In recent years there has been a wealth of debate regarding prostate cancer screening, with a concurrent increase in new imaging techniques for prostate cancer diagnosis. Imaging has been the technique of choice in lung and breast cancer screening programmes but has not been explored for prostate cancer screening. Herein, this thesis explores the role of magnetic resonance imaging (MRI) as a new approach to screen for prostate cancer.
Following an introduction to the current screening landscape, my thesis focuses on the development and validation of a fast MRI, known as a prostagram, that could serve as a viable image-based screening test. Evaluation of this new technique is performed within a prospective, population-based, blinded, cohort study which was conducted at seven primary care practices and two imaging centres. A diverse array of performance characteristics of fast MRI are compared to PSA. These encompass biopsy rates, cancer detection rates, diagnostic accuracy and patient reported experience measures.
The second half of this thesis focuses on further optimising the fast MRI protocol for screening and exploring methods of integrating it into an alternative screening pathway. The outcomes point towards a pathway which combines a low threshold PSA and a fast MRI as yielding a more acceptable balance between benefits and harms. This is followed by the development of a risk tool to address the challenges of equivocal MRI lesions.
Overall my thesis provides a balanced evaluation of fast MRI as a new screening test and the final chapter highlights outstanding challenges that must be addressed for fast MRI to progress as a legitimate screening modality. There is a requirement for all new screening tests to be evaluated in robust randomised controlled trials and the thesis concludes by setting out a phased research framework for fast MRI to enable a full evaluation over the next decade.